Edgar Filing: Altus Pharmaceuticals Inc. - Form 4

Altus Phari Form 4	maceuticals Inc.								
June 13, 20	008								
FOR		OTATES SEC	TIDITIES A	ND EVCUANC			PPROVAL		
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or						Expires:	January 31, 2005 ed average hours per		
Form 5 obligati may co <i>See</i> Ins 1(b).	ions Section 17(a) of the Publi	c Utility Hold		nange Act of 1934, ct of 1935 or Sectior f 1940	1			
(Print or Type	e Responses)								
1. Name and Address of Reporting Person <u>*</u> LEFF JONATHAN S			ool	Ticker or Trading	5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (te of Earliest Tra	-	(Check	c all applicabl	e)		
WARBUR EQUITY	RG PINCUS PRIV VIII, L.P., 466 CON AVENUE	(Mor	ith/Day/Year) 2/2008	msaction	X Director Officer (give t below)	$\begin{array}{c} \underline{X} 10^{\circ} \\ \underline{X} 0^{\circ} \\ below \end{array}$	% Owner ler (specify		
	(Street)		Amendment, Dat	-	6. Individual or Joint/Group Filing(Check				
NEW VOI	DV NV 10017	Filed	(Month/Day/Year)		Applicable Line) _X_ Form filed by O Form filed by M				
	RK, NY 10017				Person				
(City)	(State)	(Zip)	Fable I - Non-D	erivative Securitie	s Acquired, Disposed of,	, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, any	if Transaction Code	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Amount (D) Pri	Securities Fe Beneficially (I Owned (I Following (I Reported Transaction(s) (Instr. 3 and 4)	orm: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Re	eport on a separate line	e for each class of	securities benefi	cially owned direct	y or indirectly.				
				information co required to res	respond to the collect ontained in this form a spond unless the form rently valid OMB cont	are not 1	SEC 1474 (9-02)		
	Tab			iired, Disposed of, options, convertib	or Beneficially Owned le securities)				
1. Title of Derivative		saction Date 3A h/Day/Year) Exe	Deemed cution Date, if	4. 5. Num Transactionof Deri	ber 6. Date Exercisat vative Expiration Date		7. Title and Amount of Underlying Securities	8. D	

Edgar Filing: Altus Pharmaceuticals Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	Securi Acquir (A) or Dispos (D) (Instr. and 5)	ed ed of	(Month/Day	/Year)	(Instr. 3 and	4)	S (1
				Code V	7 (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Common Stock Option (Right to buy)	\$ 3.93	06/12/2008		А	8,722	2	<u>(1)</u>	06/12/2018	Common Stock	8,722	

Reporting Owners

Reporting Owner Name / Address	Relationships				
		10% Owner	Officer	Other	
LEFF JONATHAN S WARBURG PINCUS PRIVATE EQUITY VIII, L.P. 466 LEXINGTON AVENUE NEW YORK, NY 10017	Х	Х			
Signatures					

/s/ Kevin M. Brennan	06/13/2008			
<u>**</u> Signature of Reporting Person	Date			

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) All of such options have a term of ten years vesting over four years, with 1/16th of the options vesting every three months. All of such options become exercisable as they vest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Se (Ii